Respiratorius Project Portfolio
VAL001 has shown clearly promising experimental and clinical data against diseases such as diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin’s lymphoma.
The Company has successfully completed a phase I/IIa study that was conducted at Skåne University Hospital in Lund, Uppsala University Hospital, and Norrland University Hospital in Umeå.
Board of Directors and CEO
A competent team with extensive experience in both business development and commercialization of research findings as well as strong scientific background in relevant areas complemented with knowledge in clinical development and design of clinical trials.
Ingemar Kihlström
Chairman of the Board
Ingemar Kihlström holds a Bachelor of Science in Chemistry and Biology, a PhD in Physiology, and is an Associate Professor in Toxicology at Uppsala University. Ingemar Kihlström has extensive experience in board work and a long career in the pharmaceutical industry, with roles in research, development, and business development at Astra and Pharmacia. He has also worked as an independent consultant in life science and has been active in the financial sector as a pharmaceutical analyst at Swedbank, Aros Securities, and ABG Sundal Collier. Currently, Ingemar Kihlström serves as Chairman of the Board of Miris AB and Miris Holding AB.
Johan Drott
CEO
Johan has an extensive experience in senior positions in medical device and pharmaceutical companies with a focus on research, business development and commercialization of research findings.
Mia Lundblad
Board member
Mia Lundblad, holds a Master of Pharmacy degree from Uppsala University and a PhD in Clinical Pharmacology from Karolinska Institutet. Mia Lundblad has extensive experience in pharmaceutical research and development, project management, and business development from leading positions at Novo Nordisk, Ferring Pharmaceuticals, and Respiratorius. Currently, Mia Lundblad is the Clinical Pharmacology Scientific Director at Novo Nordisk and has previously served as CEO at Arcede Pharma.
Carl Magnus Schultz
Board member
Carl-Magnus Schultz holds a Bachelor of Science in Biomedical Chemistry from Linnaeus University, a PhD in Immunology from Lund University, and an MBA from EFL/Lund University School of Economics and Management. He also completed postdoctoral studies at the National Institutes of Health in Bethesda, USA. Carl-Magnus Schultz has extensive experience from the pharmaceutical and biotech sectors, both internationally and domestically, including research and development in infectious diseases, immuno-oncology, regenerative medicine, inflammation, and autoimmune diseases. He has held executive roles at several companies, including CEO of Cyxone, Edvince, Canimguide Therapeutics, and ImModulate Pharma, and Chief Scientific Officer at Xintela, where he was also part of the team that listed the company on Nasdaq First North Growth Market. Currently, Carl-Magnus Schultz serves as Board Member and Chief Executive Officer of HCB Development AB.
